<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212888</url>
  </required_header>
  <id_info>
    <org_study_id>2000456-01H</org_study_id>
    <secondary_id>CTA file 9427-C1574-32C</secondary_id>
    <nct_id>NCT00212888</nct_id>
  </id_info>
  <brief_title>Combination Vaccination Before HIV Treatment Interruption</brief_title>
  <official_title>A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ontario HIV Treatment Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vaccination before a structured treatment
      interruption (STI) is associated with an improvement in immune function, resulting in a
      delayed and reduced rebound in the amount of HIV virus in the blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be randomly assigned to receive the vaccines or matching placebos before
      interrupting their antiretroviral therapy at week 24.

      Dosage:

      Remune(TM) 1 ml i.m.* at weeks 0, 12, and 20; ALVAC 1 ml i.m.* at weeks 8,12, 16, and 20.

      * i.m.: injected in a muscle
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group</measure>
    <time_frame>Up to week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Detectable Virus in the ALVAC Alone Group and the Placebo Group</measure>
    <time_frame>Up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Rebound of Plasma HIV RNA Level to 10,000 Copies/ml</measure>
    <time_frame>Up to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Set-point</measure>
    <time_frame>Up to week 48</time_frame>
    <description>Viral set-point is the viral load (HIV RNA) that the body settles at within a few weeks to months after infection with HIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Viral Rebound</measure>
    <time_frame>Up to week 48</time_frame>
    <description>Magnitude of viral rebound is the amount of HIV viral load an infected person who was previously on ART and suppressed below clinical detection rebounds to following ART stoppage. This will typically be compared to the viral load before starting ART or Viral set-point discussed earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-specific Immune Function</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remune and ALVAC</intervention_name>
    <description>Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);
Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or
Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV infection (by serology)

          -  HIV RNA level below 50 copies/ml for at least two years

          -  Receiving at least 2 antiretroviral agents including at least 1 protease inhibitor or
             1 non-nucleoside reverse transcriptase inhibitor at time of screening

          -  Have CD4 counts above 500 cells/ul

          -  Have CD4/CD8 ratio above 0.5

          -  Have never had a CD4 count below 250

          -  No previous AIDS-defining opportunistic infection

          -  No previous cancer chemotherapy or other system immunosuppressive therapy (excluding
             brief courses [&lt;= 1 month] of prednisone or its equivalent)

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Hepatitis B surface antigen positive

          -  Hepatitis C antibody positive

          -  AST, ALT, ALP, creatinine, urea above three times the normal upper limit

          -  Blood abnormalities (hemoglobin lower than 100, white blood cell count [WBC] lower
             than 1500 or platelets lower than 100)

          -  Allergies to components of Remune™ or ALVAC

          -  Contraindications to vaccine components

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan B Angel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hotel-Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>March 28, 2017</results_first_submitted>
  <results_first_submitted_qc>March 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2019</results_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ALVAC With Remune</title>
          <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="P2">
          <title>ALVAC With Remune Placebo</title>
          <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="P3">
          <title>Both Placebos</title>
          <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALVAC With Remune</title>
          <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="B2">
          <title>ALVAC With Remune Placebo</title>
          <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="B3">
          <title>Both Placebos</title>
          <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" lower_limit="32.2" upper_limit="45.8"/>
                    <measurement group_id="B2" value="41.5" lower_limit="35.7" upper_limit="49.6"/>
                    <measurement group_id="B3" value="43.4" lower_limit="39.3" upper_limit="48.2"/>
                    <measurement group_id="B4" value="41.8" lower_limit="37.3" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration on ART</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.61" lower_limit="2.47" upper_limit="5.92"/>
                    <measurement group_id="B2" value="5.15" lower_limit="2.98" upper_limit="7.08"/>
                    <measurement group_id="B3" value="5.18" lower_limit="3.51" upper_limit="8.11"/>
                    <measurement group_id="B4" value="4.89" lower_limit="2.85" upper_limit="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline CD4 cell count</title>
          <units>cells/ul</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="771" lower_limit="660" upper_limit="970"/>
                    <measurement group_id="B2" value="658" lower_limit="514" upper_limit="1029"/>
                    <measurement group_id="B3" value="848" lower_limit="576" upper_limit="953"/>
                    <measurement group_id="B4" value="768" lower_limit="568" upper_limit="957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline CD4%</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" lower_limit="34.0" upper_limit="45.0"/>
                    <measurement group_id="B2" value="38.0" lower_limit="32.0" upper_limit="42.2"/>
                    <measurement group_id="B3" value="35.0" lower_limit="31.9" upper_limit="43.5"/>
                    <measurement group_id="B4" value="37.2" lower_limit="32.2" upper_limit="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 nadir</title>
          <units>cells/ul</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="347" lower_limit="259" upper_limit="454"/>
                    <measurement group_id="B2" value="326" lower_limit="272" upper_limit="482"/>
                    <measurement group_id="B3" value="368" lower_limit="277" upper_limit="497"/>
                    <measurement group_id="B4" value="353" lower_limit="268" upper_limit="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-HAART HIV-RNA</title>
          <units>log 10 (copies/ml)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="3.5" upper_limit="5.0"/>
                    <measurement group_id="B2" value="4.0" lower_limit="3.1" upper_limit="4.4"/>
                    <measurement group_id="B3" value="4.2" lower_limit="3.6" upper_limit="5.2"/>
                    <measurement group_id="B4" value="4.1" lower_limit="3.6" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of 'protective' HLA allele</title>
          <description>Protective HLA alleles include B27, B57, B58</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group</title>
        <time_frame>Up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALVAC With Remune</title>
            <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O2">
            <title>Both Placebos</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="11" upper_limit="32"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Detectable Virus in the ALVAC Alone Group and the Placebo Group</title>
        <time_frame>Up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALVAC With Remune Placebo</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O2">
            <title>Both Placebos</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Detectable Virus in the ALVAC Alone Group and the Placebo Group</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="16" upper_limit="31"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Rebound of Plasma HIV RNA Level to 10,000 Copies/ml</title>
        <time_frame>Up to week 48</time_frame>
        <population>Only participants who reached 10,000 copies/ml are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ALVAC With Remune</title>
            <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O2">
            <title>ALVAC With Remune Placebo</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O3">
            <title>Both Placebos</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Rebound of Plasma HIV RNA Level to 10,000 Copies/ml</title>
          <population>Only participants who reached 10,000 copies/ml are included in the analysis.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="O2" value="31.0" lower_limit="25" upper_limit="37"/>
                    <measurement group_id="O3" value="24.5" lower_limit="21" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Set-point</title>
        <description>Viral set-point is the viral load (HIV RNA) that the body settles at within a few weeks to months after infection with HIV.</description>
        <time_frame>Up to week 48</time_frame>
        <population>Only participants whose viral loads reached a steady state are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ALVAC With Remune</title>
            <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O2">
            <title>ALVAC With Remune Placebo</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O3">
            <title>Both Placebos</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Set-point</title>
          <description>Viral set-point is the viral load (HIV RNA) that the body settles at within a few weeks to months after infection with HIV.</description>
          <population>Only participants whose viral loads reached a steady state are included in the analysis.</population>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.4" upper_limit="4.7"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.4"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.8" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Viral Rebound</title>
        <description>Magnitude of viral rebound is the amount of HIV viral load an infected person who was previously on ART and suppressed below clinical detection rebounds to following ART stoppage. This will typically be compared to the viral load before starting ART or Viral set-point discussed earlier.</description>
        <time_frame>Up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALVAC With Remune</title>
            <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O2">
            <title>ALVAC With Remune Placebo</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O3">
            <title>Both Placebos</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Viral Rebound</title>
          <description>Magnitude of viral rebound is the amount of HIV viral load an infected person who was previously on ART and suppressed below clinical detection rebounds to following ART stoppage. This will typically be compared to the viral load before starting ART or Viral set-point discussed earlier.</description>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.2" upper_limit="5.2"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.3" upper_limit="5.4"/>
                    <measurement group_id="O3" value="5.0" lower_limit="4.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-specific Immune Function</title>
        <time_frame>at week 48</time_frame>
        <population>Data not collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>ALVAC With Remune</title>
            <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O2">
            <title>ALVAC With Remune Placebo</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
          <group group_id="O3">
            <title>Both Placebos</title>
            <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-specific Immune Function</title>
          <population>Data not collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ALVAC With Remune</title>
          <description>Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="E2">
          <title>ALVAC With Remune Placebo</title>
          <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
        <group group_id="E3">
          <title>Both Placebos</title>
          <description>Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Subjective fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jonathan B Angel</name_or_title>
      <organization>OHRI</organization>
      <phone>613-737-8442</phone>
      <email>JANGEL@toh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

